Who are Decitabine combined with HAAG Regimen's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Decitabine plus HAAG regimen, Decitabine in combination with R-CHOP.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/decitabine-combined-with-haag-regimen.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Decitabine combined with HAAG Regimen — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Decitabine combined with HAAG Regimen (Decitabine combined with HAAG Regimen) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Hypomethylating agent combined with chemotherapy regimen. Area: Oncology.

phase 3 Hypomethylating agent combined with chemotherapy regimen DNA methyltransferase (DNMT); also targets topoisomerase II and DNA synthesis Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Decitabine combined with HAAG Regimen (Decitabine combined with HAAG Regimen) — The First Affiliated Hospital of Soochow University. Decitabine inhibits DNA methyltransferase to reactivate silenced tumor suppressor genes, combined with HAAG chemotherapy (cytarabine, aclarubicin, amsacrine, granulocyte colony-stimulating factor) to enhance cytotoxic effects in hematologic malignancies.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Decitabine combined with HAAG Regimen TARGET	Decitabine combined with HAAG Regimen	The First Affiliated Hospital of Soochow University	phase 3	Hypomethylating agent combined with chemotherapy regimen	DNA methyltransferase (DNMT); also targets topoisomerase II and DNA synthesis
Decitabine plus HAAG regimen	Decitabine plus HAAG regimen	The First Affiliated Hospital of Soochow University	phase 3	Hypomethylating agent combined with chemotherapy regimen	DNA methyltransferase (DNMT)
Decitabine in combination with R-CHOP	Decitabine in combination with R-CHOP	Second Affiliated Hospital of Nanchang University	phase 3	Hypomethylating agent combined with chemotherapy regimen	DNA methyltransferase (decitabine component); CD20, topoisomerase II, microtubule dynamics (R-CHOP components)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Hypomethylating agent combined with chemotherapy regimen class)

The First Affiliated Hospital of Soochow University · 2 drugs in this class
Second Affiliated Hospital of Nanchang University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Decitabine combined with HAAG Regimen — Competitive Intelligence Brief. https://druglandscape.com/ci/decitabine-combined-with-haag-regimen. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab